Johnson Y. N. Lau Robert Kiyoshi Hamatake Robert K. Hamatake
Despite the availability of an effective vaccine, there are still 400 million people, worldwide who are chronically infected with hepatitis B virus (HBV). For them, the vaccine, as currently applied, has no value. Given the possible consequences of HBV infection, the number of those chronically infected with HBV presents an enormous public health challenge. For example, the major etiology of hepatocellular carcinoma (HCC) is chronic infection with HBV. Although fifth in cancer incidence, worldwide, HCC/liver cancer is the third leading cause of cancer death. The high mortality as- ciated with...
Despite the availability of an effective vaccine, there are still 400 million people, worldwide who are chronically infected with hepatitis B virus (H...
Despite the availability of an effective vaccine, there are still 400 million people, worldwide who are chronically infected with hepatitis B virus (HBV). For them, the vaccine, as currently applied, has no value. Given the possible consequences of HBV infection, the number of those chronically infected with HBV presents an enormous public health challenge. For example, the major etiology of hepatocellular carcinoma (HCC) is chronic infection with HBV. Although fifth in cancer incidence, worldwide, HCC/liver cancer is the third leading cause of cancer death. The high mortality as- ciated with...
Despite the availability of an effective vaccine, there are still 400 million people, worldwide who are chronically infected with hepatitis B virus (H...
For volume 2: A broad-ranging collection of cutting-edge techniques for the study of HBV and HDV infections and for the development of therapies to treat them. In this second of two volumes, Immunology, Model Systems, and Clinical Studies, the authors focus on protocols for the study of host immune responses to infection, in vitro and in vivo models of infection, and the development of antivirals. Each fully tested protocol is described in step-by-step detail by an established expert in the field and includes a background introduction outlining the principle underlying the technique,...
For volume 2: A broad-ranging collection of cutting-edge techniques for the study of HBV and HDV infections and for the development of therapies to tr...
The identification of hepatitis C virus by Michael Houghton and his c- leagues at the Chiron Corporation nearly years ago represented a technical tour de force of modern molecular medicine. This breakthrough not only unearthed the causative agent of non-A non-B hepatitis that had eluded the best of scientists for more than 20 years, but also was symbolic of another chapter in the changing paradigm of modern science and medicine. The re- lutionary concept of identifying a pathogen without actually visualizing or detecting it will forever redefine the way we approach pathogenesis of d- eases...
The identification of hepatitis C virus by Michael Houghton and his c- leagues at the Chiron Corporation nearly years ago represented a technical tour...